Advertisement

Naloxegol Shows Promise for Opioid-Induced Constipation — Physician’s First Watch

Medical News |
June 5, 2014

Naloxegol Shows Promise for Opioid-Induced Constipation

By Kelly Young

Edited by Susan Sadoughi, MD, and Lorenzo Di Francesco, MD, FACP, FHM

An investigational drug reduces constipation among patients taking opioids for noncancer pain, according to two phase-III, industry-funded studies reported in the New England Journal of Medicine.

The trials, conducted in the U.S. and Europe, together enrolled nearly 1400 adults who had been taking an oral opioid for noncancer pain for at least 4 weeks and had confirmed opioid-induced constipation. Patients were randomized to 12.5 or 25 mg/day of naloxegol, a peripheral μ-opioid receptor antagonist, or placebo for 12 weeks. Response was defined as three or more spontaneous bowel movements per week and an increase in bowel movements over baseline.

In both studies, patients taking 25 mg of naloxegol had a significantly higher response rate than those taking placebo (roughly 40% vs. 30%). The 12.5-mg dose was significantly better than placebo in only one of the studies.

Adverse events were highest in the 25-mg group and were most often gastrointestinal.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement